Examination of ADMA Serum Level and DDAH II

Completed

• Conditions: Septic Shock; Sepsis

• Registration Number: NCT01632059
• Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Brief Summary

Examination of ADMA (Asymmetric-Dimethylarginine)-serum level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in patients with severe Sepsis and septic shock as prognostic value.

This study looks into ADMA as a good prognostic factor for sepsis. Further more the dependency of the ADMA level to the DDAH II polymorphisms is reviewed this study.

Detailed Description

Secondary targets are the mortality (28 days ICU), the length of hospitalisation in ICU and peripheral station, the severity of the illness (SAPS II score), the SOFA-score values in the progress and the procalcitonin values in the progress

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-03-13
• Study First Submitted QC: 2012-06-28
• Study First Posted: 2012-06-29
• Primary Completion: 2013-03
• Study Completion: 2017-04
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-02
• Last Update Posted: 2017-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• >18 y/o
• sepsis
• septical shock

Exclusion Criteria

• primary cardiogenic shock
• pregnancy
• breastfeeding
• non compliance
• moribund status

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ADMA serum levels	7 days	measuring of ADMA serum levels on day 1, 3, 7

Secondary Outcome Measures

Name	Time	Method
hospitalisation (ICU and peripheral)	28 days
severity of illness	28 days
DDAH Ii polymorphism	28 days
28 day mortality	28 day

Trial Locations

Locations (1)

Universitätskrankenhaus Hamburg Eppendorf; 🇩🇪 Hamburg, Germany